Form 4: National Healthcare Corp Director Abernathy Receives Stock Option Grant

Director James Paul Abernathy of National Healthcare Corp. (NHC) reports the grant of stock options on May 9, 2024.

Summary

• James Paul Abernathy, a director at National Healthcare Corp (NHC), filed a Form 4 detailing changes in beneficial ownership.
• The report indicates that Abernathy was granted options to purchase 7,500 shares of NHC common stock on May 9, 2024, at an exercise price of $96.03 per share.
• These options vest beginning May 9, 2025, and expire on May 8, 2029.
• Abernathy directly owns 34,883 shares of NHC common stock.
• Abernathy also holds options from previous grants: 5,755 from 2021 at $71.64, 7,500 from 2022 at $69.19, and 7,500 from 2023 at $55.75.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The stock option grant is a positive incentive for the director, but it doesn't necessarily reflect a significant change in the company's overall outlook.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's stock value.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common practice in the healthcare industry to incentivize executives and align their interests with those of the shareholders. The size and terms of the grant are typical for director-level compensation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across the healthcare industry.
• Companies like Brookdale Senior Living and Life Care Centers of America also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally in line with industry norms, aiming to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if it motivates the director to improve company performance and increase shareholder value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates